Related Experiment Video
Updated: May 11, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
Risk factors for bronchiectasis in children with cystic fibrosis
Peter D Sly1, Catherine L Gangell, Linping Chen
1Queensland Children's Medical Research Institute, Brisbane, Australia. p.sly@uq.edu.au
Insights
Early life neutrophil elastase activity in cystic fibrosis patients predicts bronchiectasis. This finding highlights key risk factors for early-onset lung disease in children with CF.
Area of Science:
- Pediatric Pulmonology
- Cystic Fibrosis Research
- Respiratory Medicine
Background:
- Bronchiectasis is a common and progressive complication in cystic fibrosis (CF) that develops early in infancy.
- Identifying risk factors for early bronchiectasis is crucial for timely intervention in CF patients.
Purpose of the Study:
- To determine risk factors associated with the onset and persistence of bronchiectasis in infants diagnosed with cystic fibrosis.
- To analyze data from the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) program.
Main Methods:
- Longitudinal analysis of data from 127 infants diagnosed with CF via newborn screening.
- Chest computed tomography (CT) and bronchoalveolar lavage (BAL) were performed at 3 months, 1, 2, and 3 years of age.
- Multivariate analyses were used to identify risk factors for bronchiectasis detection.
Main Results:
- The prevalence of bronchiectasis increased from 29.3% at 3 months to 61.5% by 3 years of age.
- Key risk factors identified include meconium ileus, respiratory symptoms, free neutrophil elastase activity in BAL fluid, and gas trapping on expiratory CT.
- Elevated neutrophil elastase activity at 3 months was significantly associated with persistent bronchiectasis at later ages.
Conclusions:
- Neutrophil elastase activity in bronchoalveolar lavage fluid during early infancy is a significant predictor of early-onset bronchiectasis in children with cystic fibrosis.
- These findings underscore the importance of monitoring neutrophil elastase activity for early detection and management of lung disease in CF.
Background:
Bronchiectasis develops early in the course of cystic fibrosis, being detectable in infants as young as 10 weeks of age, and is persistent and progressive. We sought to determine risk factors for the onset of bronchiectasis, using data collected by the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) intensive surveillance program.
Methods:
We examined data from 127 consecutive infants who received a diagnosis of cystic fibrosis after newborn screening. Chest computed tomography (CT) and bronchoalveolar lavage (BAL) were performed, while the children were in stable clinical condition, at 3 months and 1, 2, and 3 years of age. Longitudinal data were used to determine risk factors associated with the detection of bronchiectasis from 3 months to 3 years of age.
Results:
The point prevalence of bronchiectasis at each visit increased from 29.3% at 3 months of age to 61.5% at 3 years of age. In multivariate analyses, risk factors for bronchiectasis were presentation with meconium ileus (odds ratio, 3.17; 95% confidence interval [CI], 1.51 to 6.66; P=0.002), respiratory symptoms at the time of CT and BAL (odds ratio, 2.27; 95% CI, 1.24 to 4.14; P=0.008), free neutrophil elastase activity in BAL fluid (odds ratio, 3.02; 95% CI, 1.70 to 5.35; P<0.001), and gas trapping on expiratory CT (odds ratio, 2.05; 95% CI, 1.17 to 3.59; P=0.01). Free neutrophil elastase activity in BAL fluid at 3 months of age was associated with persistent bronchiectasis (present on two or more sequential scans), with the odds seven times as high at 12 months of age and four times as high at 3 years of age.
Conclusions:
Neutrophil elastase activity in BAL fluid in early life was associated with early bronchiectasis in children with cystic fibrosis. (Funded by the National Health and Medical Research Council of Australia and Cystic Fibrosis Foundation Therapeutics.)
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease I: Introduction
Asthma I: Introduction
Pulmonary Cycle: Exhalation

